EA202092156A1 - Модифицированные олигонуклеотиды и способы применения в лечении таупатий - Google Patents
Модифицированные олигонуклеотиды и способы применения в лечении таупатийInfo
- Publication number
- EA202092156A1 EA202092156A1 EA202092156A EA202092156A EA202092156A1 EA 202092156 A1 EA202092156 A1 EA 202092156A1 EA 202092156 A EA202092156 A EA 202092156A EA 202092156 A EA202092156 A EA 202092156A EA 202092156 A1 EA202092156 A1 EA 202092156A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- taupathy
- treatment
- application
- modified oligonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642499P | 2018-03-13 | 2018-03-13 | |
| PCT/EP2019/056312 WO2019175260A2 (en) | 2018-03-13 | 2019-03-13 | Modified oligonucleotides and methods of use in tauopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092156A1 true EA202092156A1 (ru) | 2021-04-01 |
Family
ID=65861258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092156A EA202092156A1 (ru) | 2018-03-13 | 2019-03-13 | Модифицированные олигонуклеотиды и способы применения в лечении таупатий |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11453881B2 (https=) |
| EP (2) | EP3765476B1 (https=) |
| JP (1) | JP2021515784A (https=) |
| KR (1) | KR20200131263A (https=) |
| CN (1) | CN111868068A (https=) |
| AU (1) | AU2019233612A1 (https=) |
| BR (1) | BR112020018365A2 (https=) |
| CA (1) | CA3091979A1 (https=) |
| EA (1) | EA202092156A1 (https=) |
| ES (1) | ES3063421T3 (https=) |
| IL (1) | IL277238A (https=) |
| MA (1) | MA52149A (https=) |
| MX (1) | MX2020009532A (https=) |
| SG (1) | SG11202008895WA (https=) |
| WO (1) | WO2019175260A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203395A1 (en) | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| WO2021198958A1 (en) * | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| PE20240648A1 (es) * | 2021-07-23 | 2024-04-04 | Biogen Ma Inc | Metodos para reducir la expresion de tau |
| AU2024313057A1 (en) * | 2023-06-22 | 2025-10-30 | Denali Therapeutics Inc. | Compositions and methods for modulating tau expression |
| US12551569B2 (en) | 2024-03-31 | 2026-02-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use |
| WO2026025082A1 (en) * | 2024-07-25 | 2026-01-29 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| CN1317291C (zh) * | 1999-09-10 | 2007-05-23 | 杰龙公司 | 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用 |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| DK1794313T3 (da) * | 2004-06-21 | 2013-07-22 | Proteome Sciences Plc | Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| CN109810977A (zh) * | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
| US9228189B2 (en) * | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| ES2807379T3 (es) * | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
| TWI772856B (zh) * | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| CA2971830A1 (en) * | 2014-12-29 | 2016-07-07 | Bonac Corporation | Composition containing nucleic acid molecule stably |
| AU2016215155A1 (en) * | 2015-02-04 | 2017-08-17 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| PH12018501207B1 (en) * | 2015-12-21 | 2024-02-23 | Novartis Ag | Compositions and methods for decreasing tau expression |
-
2019
- 2019-03-13 KR KR1020207027936A patent/KR20200131263A/ko not_active Ceased
- 2019-03-13 JP JP2020547392A patent/JP2021515784A/ja active Pending
- 2019-03-13 AU AU2019233612A patent/AU2019233612A1/en not_active Abandoned
- 2019-03-13 CA CA3091979A patent/CA3091979A1/en active Pending
- 2019-03-13 EP EP19712535.4A patent/EP3765476B1/en active Active
- 2019-03-13 EA EA202092156A patent/EA202092156A1/ru unknown
- 2019-03-13 BR BR112020018365-2A patent/BR112020018365A2/pt not_active Application Discontinuation
- 2019-03-13 WO PCT/EP2019/056312 patent/WO2019175260A2/en not_active Ceased
- 2019-03-13 SG SG11202008895WA patent/SG11202008895WA/en unknown
- 2019-03-13 MX MX2020009532A patent/MX2020009532A/es unknown
- 2019-03-13 ES ES19712535T patent/ES3063421T3/es active Active
- 2019-03-13 EP EP21170299.8A patent/EP3922637A1/en active Pending
- 2019-03-13 US US16/980,389 patent/US11453881B2/en active Active
- 2019-03-13 CN CN201980018910.3A patent/CN111868068A/zh active Pending
- 2019-03-13 MA MA052149A patent/MA52149A/fr unknown
-
2020
- 2020-09-09 IL IL277238A patent/IL277238A/en unknown
-
2022
- 2022-09-26 US US17/935,518 patent/US20240011029A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019175260A3 (en) | 2019-11-14 |
| KR20200131263A (ko) | 2020-11-23 |
| US20210095284A1 (en) | 2021-04-01 |
| EP3765476A2 (en) | 2021-01-20 |
| CA3091979A1 (en) | 2019-09-19 |
| EP3765476B1 (en) | 2025-11-26 |
| EP3922637A1 (en) | 2021-12-15 |
| MX2020009532A (es) | 2020-10-05 |
| MA52149A (fr) | 2021-01-20 |
| EP3765476C0 (en) | 2025-11-26 |
| ES3063421T3 (en) | 2026-04-16 |
| BR112020018365A2 (pt) | 2020-12-29 |
| SG11202008895WA (en) | 2020-10-29 |
| WO2019175260A2 (en) | 2019-09-19 |
| AU2019233612A1 (en) | 2020-09-10 |
| IL277238A (en) | 2020-10-29 |
| CN111868068A (zh) | 2020-10-30 |
| JP2021515784A (ja) | 2021-06-24 |
| US20240011029A1 (en) | 2024-01-11 |
| US11453881B2 (en) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092156A1 (ru) | Модифицированные олигонуклеотиды и способы применения в лечении таупатий | |
| IL263437B (en) | -'5 cyclo-phosphonate modified nucleotides, compositions comprising same and uses thereof | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| EP4631970A3 (en) | Nucleic acid molecules and uses thereof | |
| MX388743B (es) | Conjugados oligonucleótido-péptido. | |
| EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
| GEAP202115055A (en) | Anti-cd27 antibodies | |
| EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
| CY1115617T1 (el) | Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer | |
| MX2019002960A (es) | Oligonucleótidos modificados y métodos de uso. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| EA201891609A1 (ru) | Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
| EA201891608A1 (ru) | Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
| EA201891610A1 (ru) | Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
| EP3585818A4 (en) | ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE | |
| MX390418B (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso. | |
| BR112018003928A2 (pt) | métodos para o tratamento de doenças | |
| WO2017151860A8 (en) | Human kynureninase enzyme variants having improved pharmacological properties | |
| EA201891612A1 (ru) | Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| MX2020009296A (es) | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. |